Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE) To Close 2 Britain Facilities, To Present New Xeljanz Data

Pfizer Inc. (NYSE:PFE) has recently revealed that it is closing two manufacturing plants in Britain. The company has claimed that the move is part of the company’s efforts to restructure its global footprint and in no way a result of Britain deciding to leave the European Union (EU).

Closing Facilities

More than 700 employees will be affected in the shutdown in Britain. Pfizer has reassured that it will facilitate the best possible transition period for these employees.

Pfizer PFE pharmaceutical stock

pio3 /

The facilities include the Hospira UK Compounding factory located in London, which will be shut mid-next-year, and a packaging and distribution site located in Havant will be closed by the end of the decade.

2016 ACR/ARHP Presentation

On Monday, Pfizer Inc. (NYSE:PFE) also confirmed that it will be presenting 20 abstracts for Xeljanz (tofacitinib citrate), a Janus kinase (JAK) inhibitor, at the 2016 ACR/ARHP meeting, which will begin on Friday and last until Wednesday.

Highlights of the company’s presentations include the first presentation of the results from two Phase 3 Oral Psoriatic Arthritis Trial (OPAL) evaluating Xeljanz, OPAL Broaden and OPAL Beyond. Aside from these, new data evaluating Xeljanz for the treatment of rheumatoid arthritis are highly anticipated as well.

“The extensive data being presented at this year’s ACR/AHRP annual meeting expands upon our knowledge about the role of XELJANZ for the treatment of moderate to severe rheumatoid arthritis and also highlights its potential, if approved, for the treatment of psoriatic arthritis,” boasted Michael Corbo, Pfizer Global Product Development Chief Development Officer of Inflammation and Immunology, about the company’s undying commitment.

In the US, Xeljanz is the first— and currently only — oral JAK inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of patients with moderate-to-severe RA who have shown an inadequate or intolerance response to methotrexate.

Globally, Xeljanz is approved in 50 markets for the treatment of patients with moderate-to-severe RA who have received prior disease-modifying antirheumatic drugs (DMARDs) that eventually failed.

Xeljanz has so far been evaluated in more than 6,000 patients with moderate-to-severe RA. This reiterates the company’s commitment to further understanding the drug’s capabilities in helping RA patients and also expanding its indication.

Pfizer Inc. (NYSE:PFE) closed at $30 on Tuesday.

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.